Last reviewed 2026-04-22 · How we verify

Pulmozyme®

Pulmozyme is a recombinant human DNase that breaks down extracellular DNA in airway secretions to reduce mucus viscosity and improve lung function.

Pulmozyme is a recombinant human DNase that breaks down extracellular DNA in airway secretions to reduce mucus viscosity and improve lung function. Used for Cystic fibrosis to improve pulmonary function and reduce respiratory infections.

At a glance

Mechanism of action

The drug is an inhaled recombinant deoxyribonuclease I (DNase) that cleaves extracellular DNA present in the thick, purulent sputum of cystic fibrosis patients. By degrading DNA, it reduces the viscosity and elasticity of mucus, making it easier to expectorate and improving airway clearance. This leads to improved pulmonary function and reduced respiratory infections.

Approved indications

• Cystic fibrosis to improve pulmonary function and reduce respiratory infections

Common side effects

• Voice hoarseness
• Pharyngitis
• Laryngitis
• Chest pain
• Hemoptysis

Key clinical trials

• Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (PHASE2)
• VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema (NA)
• Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma (PHASE3)
• Usefulness of DORNASE in COVID-19 on HFNO (PHASE4)
• RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum (PHASE4)
• Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19 (PHASE3)
• Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis (PHASE3)
• A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.